ライフサイエンスコーパス: venous thromboembolism

1 er, and pulmonary embolism), and raloxifene (venous thromboembolism).

2 s greater than those used for prophylaxis of venous thromboembolism.

3 aban with warfarin in the treatment of acute venous thromboembolism.

4 in K antagonists during extended therapy for venous thromboembolism.

5 entional anticoagulants for the treatment of venous thromboembolism.

6 e meta-analysis of heart failure and risk of venous thromboembolism.

7 arin in the treatment of patients with acute venous thromboembolism.

8 lants in the management of cancer-associated venous thromboembolism.

9 th severe disease, have an increased risk of venous thromboembolism.

10 lure is a common independent risk factor for venous thromboembolism.

11 n thrombosis and pulmonary embolism comprise venous thromboembolism.

12 n hospital had an RR of 1.51 (1.36-1.68) for venous thromboembolism.

13 tended treatment for prevention of recurrent venous thromboembolism.

14 ansfusion through a multi-lumen PICC, 61 had venous thromboembolism.

15 with antiphospholipid syndrome and previous venous thromboembolism.

16 elvis in patients who had a first unprovoked venous thromboembolism.

17 s low among patients with a first unprovoked venous thromboembolism.

18 ent developments in the imaging diagnosis of venous thromboembolism.

19 A total of 289 patients (7.7%) developed venous thromboembolism.

20 e primary efficacy outcome was recurrence of venous thromboembolism.

21 ult cancer in a person who has an unprovoked venous thromboembolism.

22 in the treatment and secondary prevention of venous thromboembolism.

23 the heparin group; P=0.61), and no recurrent venous thromboembolism.

24 the standard treatment for cancer-associated venous thromboembolism.

25 sm and major bleeding in patients with acute venous thromboembolism.

26 with a low likelihood of subsequent clinical venous thromboembolism.

27 emic stroke, acute myocardial infarction, or venous thromboembolism.

28 suggest a beneficial effect of statin use on venous thromboembolism.

29 n both patients with atrial fibrillation and venous thromboembolism.

30 ion in atrial fibrillation and management of venous thromboembolism.

31 effective for the prevention of symptomatic venous thromboembolism.

32 roximal deep-vein thrombosis and symptomatic venous thromboembolism.

33 ), stroke (11 more cases [95% CI, 2 to 23]), venous thromboembolism (11 more cases [95% CI, 3 to 22])

34 luded neutropenia (36 [44%] vs 11 [28%]) and venous thromboembolism (16 [20%] vs four [10%]).

35 setting of major, transient risk factors for venous thromboembolism; (2) do not routinely transfuse f

36 (876 more cases [95% CI, 606 to 1168]), and venous thromboembolism (21 more cases [95% CI, 12 to 33]

37 Outcomes were venous thromboembolism, acute myocardial infarction, isc

38 there was a significantly increased risk of venous thromboembolism (adjusted HR 1.24, 95% CI 1.01-1.

39 boprophylaxis to prevent clinically apparent venous thromboembolism after knee arthroscopy or casting

40 We compared the incidence of symptomatic venous thromboembolism after these procedures between pa

41 cancer have a substantial risk of recurrent venous thromboembolism and bleeding during anticoagulant

42 nts, in clinical practice many patients with venous thromboembolism and cancer do not receive this tr

43 Patients with venous thromboembolism and cancer have a substantial ris

44 es have investigated the association between venous thromboembolism and heart failure, but have yield

45 asma levels of FXI have been associated with venous thromboembolism and ischemic stroke, its deficien

46 ndomized trials reporting rates of recurrent venous thromboembolism and major bleeding in patients wi

47 ere the cumulative incidences of symptomatic venous thromboembolism and major bleeding within 3 month

48 clinical and safety outcomes were recurrent venous thromboembolism and major bleeding, respectively.

49 t of anticoagulation for indications such as venous thromboembolism and mechanical heart valves.

50 Venous thromboembolism and mortality each occurred in on

51 Grade 3/4 venous thromboembolism and peripheral neuropathy were ra

52 at increase the risk of pregnancy-associated venous thromboembolism and pregnancy loss and can also i

53 or-mediated procoagulatory activity leads to venous thromboembolism and supports metastasis in cancer

54 nd 49 years of age who had not had cancer or venous thromboembolism and who had not received treatmen

55 incidental SSPE is associated with recurrent venous thromboembolism and, when symptomatic, may advers

56 ength of stay outcomes, and the processes of venous-thromboembolism and stress ulcer prophylaxis prov

57 fety outcomes were major bleeding, recurrent venous thromboembolism, and all-cause mortality.

58 ical applications within atherosclerosis and venous thromboembolism, and explores the potential for m

59 n-treated patients with atrial fibrillation, venous thromboembolism, and mechanical valve replacement

60 agic shock-associated in-hospital mortality, venous thromboembolism, and multiple organ failure.

61 deep venous thrombosis, pulmonary embolism, venous thromboembolism, and myocardial infarction by dev

62 plications, such as urinary tract infection, venous thromboembolism, and myocardial infarction, on th

63 disease, heart failure, arrhythmias, stroke, venous thromboembolism, and peripheral vascular disease.

64 ufficiency, urinary tract infection, stroke, venous thromboembolism, and postoperative death continue

65 e from sepsis, hospital acquired infections, venous thromboembolism, and pulmonary embolism.

66 was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome

67 atrial fibrillation and for the treatment of venous thromboembolism, and they are comparable to low-m

68 , those with a personal or family history of venous thromboembolism, and those receiving vasopressors

69 r the treatment of patients with cancer with venous thromboembolism, and with less clinically relevan

70 y and their contribution to the incidence of venous thromboembolism are not well understood in the cl

71 ated with myocardial infarction, stroke, and venous thromboembolism, are challenging to address.

72 S) is an autoimmune disease characterized by venous thromboembolism, arterial thrombosis, and obstetr

73 rimary efficacy outcome was the incidence of venous thromboembolism (assessed by mandatory bilateral

74 eatment analysis, the incidence of recurrent venous thromboembolism at 3 months was 1.1% (0.8-1.4; 44

75 ath, major and minor bleeding, and recurrent venous thromboembolism at 90 days.

76 lysis, the cumulative incidence of recurrent venous thromboembolism between 3 and 12 months was 0.3%

77 controls, collected as part of the Swedish "Venous Thromboembolism Biomarker Study," using suspensio

78 has been suggested as a new risk factor for venous thromboembolism, but its prognostic value is uncl

79 tion in atrial fibrillation and treatment of venous thromboembolism, but little is known about rivaro

80 or the treatment and secondary prevention of venous thromboembolism, but whether it is useful in pati

81 tor (older than 65 years, male sex, previous venous thromboembolism, cancer, autoimmune disease, thro

82 Any fractures, peripheral arterial disease, venous thromboembolism, cardiac-related complications, d

83 al effects of aspirin, such as prevention of venous thromboembolism, chemoprevention of colorectal (a

84 with rosuvastatin having the lowest risk on venous thromboembolism compared with other statins 0.57

85 rapy with rosuvastatin significantly reduced venous thromboembolism compared with other statins.

86 entral catheters (PICCs) affects the risk of venous thromboembolism compared with transfusion through

87 nrolled patients with atrial fibrillation or venous thromboembolism, compared a novel oral anticoagul

88 Venous thromboembolism complications in-hospital and up

89 ncer, while non-pulmonary conditions include venous thromboembolism, coronary artery disease, congest

90 assessed the association of statin use with venous thromboembolism, deep vein thrombosis, or pulmona

91 lacebo or no treatment and collected data on venous thromboembolism, deep vein thrombosis, or pulmona

92 cidence of adjudicated symptomatic recurrent venous thromboembolism defined as a composite of deep ve

93 Venous thromboembolism developed in 482 (5%) of 10 604 p

94 roportion of patients experiencing recurrent venous thromboembolism during 3 months of treatment were

95 of these patients with symptomatic recurrent venous thromboembolism during the 12-month study period,

96 cidence of adjudicated symptomatic recurrent venous thromboembolism evaluated for each of the time in

97 t to which statins are associated with first venous thromboembolism events.

98 olds; their 3-month incidence of symptomatic venous thromboembolism (failure rate) was also estimated

99 Venous thromboembolism following major cancer surgery wa

100 to nonfederal California hospitals for acute venous thromboembolism from 2005 to 2010.

101 Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence af

102 ostic approaches for patients with suspected venous thromboembolism have been developed over the year

103 sociated with an increased risk of recurrent venous thromboembolism (hazard ratio [HR], 1.42; 95% cre

104 ism included a personal or family history of venous thromboembolism (hazard ratio, 1.64; 95% CI, 1.03

105 80), peripheral arterial disease (HR, 2.25), venous thromboembolism (HR, 1.52), cardiac-related compl

106 owing outcomes: acute cardiac event; stroke; venous thromboembolism; hypertension; and diabetes melli

107 t pooled for hypertension (I(2) = 95.0%) and venous thromboembolism (I(2) = 82.3%).

108 The adjusted hazard ratio (HR) for venous thromboembolism in all patients whose transfusion

109 Among patients with venous thromboembolism in equipoise for continued antico

110 icacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL pat

111 (F5(L) ) is a common genetic risk factor for venous thromboembolism in humans.

112 We also assessed rates of venous thromboembolism in patients in different settings

113 arched for studies investigating the risk of venous thromboembolism in patients in hospital with hear

114 olecular-weight heparin for the treatment of venous thromboembolism in patients with cancer are warra

115 ify the absolute and relative risks (RR) for venous thromboembolism in patients with heart failure af

116 The overall frequency of recurrent venous thromboembolism in patients with only a history o

117 in the treatment and prevention of recurrent venous thromboembolism in patients with pulmonary emboli

118 mportant clinical entity among patients with venous thromboembolism in the presence of intracardiac o

119 s of myocardial infarction, and 720 cases of venous thromboembolism) in the period of 1 year plus up

120 e ratios were observed for pregnancy-related venous thromboembolism (incidence rate ratio, 2.22; 95%

121 ylaxis failure as measured by development of venous thromboembolism included a personal or family his

122 ly diagnosed non-fatal and fatal arterial or venous thromboembolism, including myocardial infarction

123 ere mortality, multiple organ failure (MOF), venous thromboembolism, infection, stroke, ventilator-fr

124 n, IR=77.5 in males and 59.5 in females; and venous thromboembolism, IR=115 to 269.

125 The reported incidence of venous thromboembolism is 1.5-3.4% of infected patients,

126 Venous thromboembolism is a common complication in patie

127 Venous thromboembolism is a common complication of cance

128 Venous thromboembolism is a known but rare complication

129 Venous thromboembolism is a major global health problem

130 Venous thromboembolism is an important complication foll

131 ly, but its benefit for preventing recurrent venous thromboembolism is not well known.

132 Empirical data from the GENEVA project on venous thromboembolism is used to illustrate the propose

133 Oral anticoagulant therapy for venous thromboembolism is very effective.

134 Rates of recurrent venous thromboembolism, major bleeding, and unrelated de

135 ission and the 1-year incidence of recurrent venous thromboembolism manifested as pulmonary embolism

136 Venous thromboembolism may be the earliest sign of cance

137 e, MR=42.3; atrial fibrillation, MR=1.7; and venous thromboembolism, MR=9.4 to 32.3.

138 In patients with venous thromboembolism, no increased risk of substantial

139 Venous thromboembolism occurred in 10 of the 719 patient

140 Recurrent venous thromboembolism occurred in 11 (3%) of 414 and 20

141 Recurrent venous thromboembolism occurred in 14 (3%) of 465 patien

142 Recurrent venous thromboembolism occurred in 14 (4%) of 378 patien

143 at baseline or during treatment), recurrent venous thromboembolism occurred in 16 (5%) of 354 patien

144 Recurrent venous thromboembolism occurred in 3 patients in the war

145 Recurrent venous thromboembolism occurred in 41 patients (7.9%) in

146 Venous thromboembolism occurred in 5 of the 731 patients

147 During the 3-month follow-up, recurrent venous thromboembolism occurred in two patients (0.73%;

148 Venous thromboembolism occurs commonly in patients with

149 Venous thromboembolism occurs frequently in patients wit

150 Venous thromboembolism occurs in up to one-third of pati

151 ents with a history of HIT (eg, treatment of venous thromboembolism or acute coronary syndrome), pref

152 f TSOACs compared with VKAs in patients with venous thromboembolism or atrial fibrillation.

153 imary outcome was the composite of recurrent venous thromboembolism or major bleeding at 18 months af

154 primary outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 m

155 espect to the composite outcome of recurrent venous thromboembolism or major bleeding.

156 cipants (aged >/=75 years) treated for acute venous thromboembolism or stroke prevention in atrial fi

157 omen with thrombophilia at increased risk of venous thromboembolism or with previous placenta-mediate

158 te infection (OR = 2.19, 95% CI: 1.53-3.13), venous thromboembolism (OR = 1.92, 95% CI: 1.08-3.43), a

159 hock-associated death (OR, 2.44; p = 0.001), venous thromboembolism (OR, 1.73; p < 0.001), and multip

160 al infarction (OR: 1.44; 95% CI: 1.22-1.70), venous thromboembolism (OR:2.11; 95% CI: 1.70-2.61), acu

161 site of major bleeding, INR of 4 or greater, venous thromboembolism, or death.

162 risk of major bleeding, INR of 4 or greater, venous thromboembolism, or death.

163 orted associations between statins and first venous thromboembolism outcomes were identified from MED

164 nd 4.1 (95% confidence interval 2.5-6.4) for venous thromboembolism patients, respectively.

165 dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-medi

166 ive APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration

167 rophylaxis (omega, 0.43; 95% CI, 0.34-0.54), venous thromboembolism prophylaxis (omega, 0.57; 95% CI,

168 perating characteristic curve % differences: venous thromboembolism prophylaxis, 3.4%; stress ulcer p

169 th of stay, bed elevation to >/=30 degrees , venous thromboembolism prophylaxis, diet administration,

170 t positioning, oral care with chlorhexidine, venous thromboembolism prophylaxis, stress ulcer prophyl

171 Independent predictors for venous thromboembolism, proximal leg deep vein thrombosi

172 emic attack, renal insufficiency or failure, venous thromboembolism, pulmonary embolism, and operativ

173 The overall median symptomatic venous thromboembolism rate was 2.48% (IQR 0.84-5.61); r

174 were eligible for inclusion if they reported venous thromboembolism rates (number of events per follo

175 ith 59 cohorts included in the assessment of venous thromboembolism rates and 46 cohorts included in

176 Venous thromboembolism rates are low and largely unchang

177 Venous thromboembolism rates varied widely in patients i

178 ular dysfunction and reported that recurrent venous thromboembolism rates were lower with edoxaban th

179 Venous thromboembolism recurred in 15 of the 307 patient

180 that factor XI contributes to postoperative venous thromboembolism; reducing factor XI levels in pat

181 Although many patients with venous thromboembolism require extended treatment, it is

182 ivery through a peripheral intravenous line, venous thromboembolism risk was not elevated if transfus

183 (RR, 0.71; 95% CI, 0.51-0.99), 33 vs 38 for venous thromboembolism (RR, 0.85; 95% CI, 0.54-1.34), an

184 y distress syndrome, multiple organ failure, venous thromboembolism, sepsis, and transfusion-related

185 As part of a larger case-control study of venous thromboembolism, serum levels of 51 proteins impl

186 Venous thromboembolism showed an estimated annual percen

187 ccult Malignancy in Patients with Idiopathic Venous Thromboembolism (SOME) trial.

188 composite primary outcome variables (risk of venous thromboembolism, stroke, or transient ischemic at

189 0-day rate of major adverse outcomes (death, venous thromboembolism, subsequent intervention, and fai

190 on to anticoagulation in patients with acute venous thromboembolism, their benefit-risk ratio is uncl

191 se results indicate that platelet APP limits venous thromboembolism through a negative regulation of

192 ncer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-w

193 hase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily riva

194 ed for obese or IBD patients with unprovoked venous thromboembolism unless there is a high risk of bl

195 ne the risk factors for 30-day postdischarge venous thromboembolism (VTE) after bariatric surgery and

196 ely stratify risk or provide prophylaxis for venous thromboembolism (VTE) among surgical patients.

197 ing evidence supports an association between venous thromboembolism (VTE) and arterial thrombotic dis

198 WAS) have confirmed known risk mutations for venous thromboembolism (VTE) and identified a number of

199 xtensively investigated for the diagnosis of venous thromboembolism (VTE) and is used routinely for t

200 We quantified the risk of venous thromboembolism (VTE) and ischemic stroke (IS) du

201 Both issues influence the occurrence of venous thromboembolism (VTE) and may impact Medicare rei

202 k for recurrence in patients with unprovoked venous thromboembolism (VTE) and may justify stopping tr

203 Studies on long-term mortality after venous thromboembolism (VTE) are sparse.

204 patients with a first unprovoked symptomatic venous thromboembolism (VTE) are unknown.

205 r thrombomodulin) that increased the risk of venous thromboembolism (VTE) by about 2.3-fold in Africa

206 Venous thromboembolism (VTE) clusters in families, but t

207 ls including a total of 27,023 patients with venous thromboembolism (VTE) compared a direct oral anti

208 ning estrogens, is associated with recurrent venous thromboembolism (VTE) during anticoagulation.

209 The primary end point was recurrent venous thromboembolism (VTE) during the 1 year after dis

210 The annual number of US venous thromboembolism (VTE) events, the number of poten

211 ited data on the prevalence and mortality of venous thromboembolism (VTE) following oncologic surgery

212 Impact on the timing of first postpartum venous thromboembolism (VTE) for women with specific ris

213 timating recurrence risk after an unprovoked venous thromboembolism (VTE) has been developed to ident

214 The incidence of pediatric venous thromboembolism (VTE) has been increasing signifi

215 ave been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial.

216 or vena cava (IVC) filters for prevention of venous thromboembolism (VTE) in bariatric surgery is a c

217 r for predicting initial, but not recurrent, venous thromboembolism (VTE) in cancer, a setting in whi

218 To review the current literature on venous thromboembolism (VTE) in critically ill children.

219 ded over warfarin for the treatment of acute venous thromboembolism (VTE) in patients with active can

220 Although rare, the incidence of venous thromboembolism (VTE) in pediatric trauma patient

221 rmed a meta-analysis to evaluate the risk of venous thromboembolism (VTE) in pregnant women with esse

222 : Prophylactic enoxaparin is used to prevent venous thromboembolism (VTE) in surgical and trauma pati

223 Venous thromboembolism (VTE) is a common complication of

224 Venous thromboembolism (VTE) is a common disease associa

225 Venous thromboembolism (VTE) is a leading cause of mater

226 Postpartum venous thromboembolism (VTE) is a potentially fatal and

227 Venous thromboembolism (VTE) is an important complicatio

228 Venous thromboembolism (VTE) is common in cancer patient

229 Venous thromboembolism (VTE) is common in patients with

230 Appropriate risk stratification for venous thromboembolism (VTE) is essential to providing a

231 The risk for venous thromboembolism (VTE) is increased in cancer and

232 Venous thromboembolism (VTE) is increasingly diagnosed i

233 Venous thromboembolism (VTE) is the second leading cause

234 Venous thromboembolism (VTE) is the third most common li

235 duration of anticoagulation in patients with venous thromboembolism (VTE) is uncertain.

236 agulation in patients with cancer-associated venous thromboembolism (VTE) is unknown.

237 sults, our study replicated previously known venous thromboembolism (VTE) loci near the F5, FGA-FGG,

238 women taking oral anticoagulant therapy for venous thromboembolism (VTE) may use estrogen or progest

239 ening for cancer in patients with unprovoked venous thromboembolism (VTE) often is considered, but cl

240 superior to unfractionated heparin (UH) for venous thromboembolism (VTE) prophylaxis in patients wit

241 Active cancer is the major predictor of venous thromboembolism (VTE) recurrence, but further str

242 Venous thromboembolism (VTE) surveillance practices in h

243 Blacks are thought to have a higher risk of venous thromboembolism (VTE) than whites.

244 In patients with a first unprovoked venous thromboembolism (VTE) the risk of recurrent VTE r

245 al patients individually risk stratified for venous thromboembolism (VTE) using Caprini scores.

246 e, no study has assessed whether the risk of venous thromboembolism (VTE) varies with blunt or penetr

247 Blood, Donato et al report that treatment of venous thromboembolism (VTE) with anticoagulation does n

248 patients at high risk for the development of venous thromboembolism (VTE) would provide a basis for c

249 iobank to understand the inherited basis for venous thromboembolism (VTE), a leading cause of cardiov

250 as been associated with an increased risk of venous thromboembolism (VTE), but the association can be

251 ity plasma biomarkers for predicting risk of venous thromboembolism (VTE), but thus far, such markers

252 Venous thromboembolism (VTE), caused by altered hemostas

253 Venous thromboembolism (VTE), comprising deep vein throm

254 Infections are risk factors for venous thromboembolism (VTE), especially if severe and a

255 ling first-degree relatives of patients with venous thromboembolism (VTE), it is important to know wh

256 th differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortal

257 Registry to report on the high incidence of venous thromboembolism (VTE), mortality, and arterial th

258 with breast cancer are at increased risk of venous thromboembolism (VTE), particularly in the peridi

259 Venous thromboembolism (VTE), the third leading cause of

260 pulmonary embolism are collectively known as venous thromboembolism (VTE), which is a common vascular

261 t 3 months to complete "active treatment" of venous thromboembolism (VTE), with further treatment ser

262 uma patients are at high risk for developing venous thromboembolism (VTE).

263 herosclerosis may be associated with risk of venous thromboembolism (VTE).

264 may be complicated by adverse events such as venous thromboembolism (VTE).

265 is a risk marker for incident and recurrent venous thromboembolism (VTE).

266 reased surgical duration on the incidence of venous thromboembolism (VTE).

267 germ cell tumors (GCTs), is associated with venous thromboembolism (VTE).

268 ndition associated with an increased risk of venous thromboembolism (VTE).

269 FHMI) has been shown to increase the risk of venous thromboembolism (VTE).

270 cancer are considered to be at high risk for venous thromboembolism (VTE).

271 nal cardiovascular disease risk factors with venous thromboembolism (VTE).

272 , stroke, and transient ischemic attack) and venous thromboembolism (VTE).

273 dentify ENTPD1 polymorphisms associated with venous thromboembolism (VTE).

274 Cancer patients have an increased risk of venous thromboembolism (VTE).

275 s) regarding serious adverse events, such as venous thromboembolism (VTE).

276 vitamin K antagonists (VKA) in patients with venous thromboembolism (VTE).

277 nce implicates platelets as key mediators of venous thromboembolism (VTE).

278 deep vein thrombosis and pulmonary embolism (venous thromboembolism, VTE), biomarkers or genetic risk

279 In observational studies, the pooled RR for venous thromboembolism was 0.75 (95% CI 0.65-0.87; p<0.0

280 In RCTs, the RR for venous thromboembolism was 0.85 (0.73-0.99; p=0.038) whe

281 The frequency of recurrent venous thromboembolism was 1.4% (36/2505) in the rivarox

282 follow-up of 7 years, the incidence rate of venous thromboembolism was 18.0/1000 person-years (95% c

283 Venous thromboembolism was diagnosed in 1141 of 536,423

284 The rate of recurrent venous thromboembolism was lower but the rate of major b

285 , but no significant difference in recurrent venous thromboembolism was seen over the 24-month follow

286 IETE (Computerized Registry of Patients With Venous Thromboembolism), we assessed the association bet

287 Rates of major bleeding and recurrent venous thromboembolism were low in rivaroxaban-treated p

288 th complicated recoveries (death, infection, venous thromboembolism) were matched with 12 cases with

289 Careful monitoring for venous thromboembolism when transfusing red blood cells

290 Venous thromboembolism (which comprised events of pulmon

291 een suggested to have a protective effect on venous thromboembolism (which includes deep vein thrombo

292 risk of death only among patients with acute venous thromboembolism who had a contraindication to ant

293 udy, 615 patients with first-ever unprovoked venous thromboembolism who had completed 3 to 12 months

294 ve alternative to warfarin for patients with venous thromboembolism who require extended treatment fo

295 ndrome who were taking warfarin for previous venous thromboembolism, with a target international norm

296 sk of recurrence in patients with unprovoked venous thromboembolism, with no apparent increase of ble

297 a contraindication to anticoagulation, prior venous thromboembolism within 180 days, or diagnosis of

298 tect animals from activated platelet-induced venous thromboembolism without increasing bleeding from

299 for Long-term and Initial Anticoagulation in venous thromboembolism (XALIA) was a multicentre, intern

300 ies are available for the treatment of acute venous thromboembolism, yet little guidance exists regar